Soluble epoxide hydrolase inhibitor, TUPS, protects against isoprenaline-induced cardiac hypertrophy.
about
Soluble epoxide hydrolase: A potential target for metabolic diseasesSoluble epoxide hydrolase: gene structure, expression and deletionOpposite effects of gene deficiency and pharmacological inhibition of soluble epoxide hydrolase on cardiac fibrosisInhibition of soluble epoxide hydrolase increases coronary perfusion in miceCYP2J2 and its metabolites (epoxyeicosatrienoic acids) attenuate cardiac hypertrophy by activating AMPKα2 and enhancing nuclear translocation of Akt1.Autonomic cardiac innervation: development and adult plasticity.Development of cellular hypertrophy by 8-hydroxyeicosatetraenoic acid in the human ventricular cardiomyocyte, RL-14 cell line, is implicated by MAPK and NF-κB.5-, 12- and 15-Hydroxyeicosatetraenoic acids induce cellular hypertrophy in the human ventricular cardiomyocyte, RL-14 cell line, through MAPK- and NF-κB-dependent mechanism.Cardioprotective Effect of Ulmus wallichiana Planchon in β-Adrenergic Agonist Induced Cardiac HypertrophySoluble epoxide hydrolase is involved in the development of atherosclerosis and arterial neointima formation by regulating smooth muscle cell migration.Screening of soluble epoxide hydrolase inhibitory ingredients from traditional Chinese medicines for anti-inflammatory use.The Role of Soluble Epoxide Hydrolase Enzyme on Daunorubicin-Mediated Cardiotoxicity.
P2860
Q28270454-93CDC957-CE7E-4359-BDF8-CA8C861D091AQ28291292-E9D08234-9423-4602-A52A-149461EA6AEEQ28383719-B2365F8D-7705-4356-BF67-4E51A2D7AB5AQ35877561-616818F7-DC05-4E4A-A638-C0F36E6071D7Q37235552-350FF550-F4B1-4429-B905-9006E32DEB67Q37496525-6A02C5E5-1A76-4F16-9B2E-3C2BB6F95A3BQ38825803-97B375E0-9CEC-480F-AF3F-E44F55ADC352Q38918680-C21D7B0C-74DF-4AE8-99FC-E32A8C897BA5Q39576954-945267D8-29B1-4477-92E0-DAF8FBF92978Q40447038-8248DC07-F780-4C1A-8730-FF8BBC4FC37EQ47143230-90263C6D-3826-4138-8C94-E09833E1CC03Q47339443-6444854E-7FCB-46D0-B9F7-D4F9E06A0759
P2860
Soluble epoxide hydrolase inhibitor, TUPS, protects against isoprenaline-induced cardiac hypertrophy.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Soluble epoxide hydrolase inhi ...... e-induced cardiac hypertrophy.
@ast
Soluble epoxide hydrolase inhi ...... e-induced cardiac hypertrophy.
@en
type
label
Soluble epoxide hydrolase inhi ...... e-induced cardiac hypertrophy.
@ast
Soluble epoxide hydrolase inhi ...... e-induced cardiac hypertrophy.
@en
prefLabel
Soluble epoxide hydrolase inhi ...... e-induced cardiac hypertrophy.
@ast
Soluble epoxide hydrolase inhi ...... e-induced cardiac hypertrophy.
@en
P2093
P2860
P356
P1476
Soluble epoxide hydrolase inhi ...... ne-induced cardiac hypertrophy
@en
P2093
Ayman O S El-Kadi
Bruce D Hammock
Ghada Abdelhamid
Hassan N Althurwi
Mandy M Y Tse
P2860
P304
P356
10.1111/BPH.12066
P407
P577
2013-04-01T00:00:00Z